Cargando…
The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients
BACKGROUND: The pathogenesis of multiple sclerosis (MS) involves immune-mediated mechanisms, and disease-modifying therapies (DMTs) administered in MS have immunomodulatory effects. The concern about MS patients' susceptibility to coronavirus disease 2019 (COVID-19) has prompted several studies...
Autores principales: | Oncel, Ibrahim, Alici, Nurettin, Solmaz, Ismail, Oge, Dogan Dinc, Ozsurekci, Yasemin, Anlar, Banu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186527/ https://www.ncbi.nlm.nih.gov/pubmed/35772229 http://dx.doi.org/10.1016/j.pediatrneurol.2022.06.004 |
Ejemplares similares
-
Evolution of clinically isolated syndrome to pediatric-onset multiple sclerosis and a review of the literature
por: SOLMAZ, İsmail, et al.
Publicado: (2022) -
A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients
por: SOLMAZ, İsmail, et al.
Publicado: (2022) -
New-Onset Ocular Myasthenia after Multisystem Inflammatory Syndrome in Children
por: Yavuz, Pınar, et al.
Publicado: (2022) -
A comparison of blood stream infections with extended spectrum beta-lactamase-producing and non-producing Klebsiella pneumoniae in pediatric patients
por: Tanır Basaranoglu, Sevgen, et al.
Publicado: (2017) -
Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas
por: Samia, Pauline, et al.
Publicado: (2022)